In investment projects within the pharmaceutical industry, project delays often cause immense economic damage—arising from direct cost overruns as well as lost revenue resulting from delayed facility availability. Nevertheless, delays of just a few days are frequently ignored or tolerated in day-to-day project operations. If such "micro-delays" recur, they accumulate into delays of weeks or even months, resulting in economic losses running into the millions. This presentation examines the project audit as an effective tool for quality assurance in project management.